Module 20
EU GMP Annex 2 and Biological Medicinal Product Manufacture
Course Overview
This course provides the advanced understanding needed by professionals manufacturing, quality-assuring, regulating or commercialising biological medicinal products for human use, working to the EU GMP Annex 2 framework and the wider regulatory expectations that apply to biologicals.
Biological medicinal products are not simply chemically complex small molecules. They are recombinant proteins, monoclonal antibodies, vaccines, blood and plasma products, gene therapies, cell therapies, allergen products and tissue-engineered products whose manufacture relies on living cells, biological starting materials, complex multi-step processing and analytical methods that often cannot characterise the active substance as fully as a small molecule API can be characterised. The regulatory framework reflects this reality: biological product manufacture is governed by EU GMP Annex 2, supplemented by ICH Q5 series guidelines and substantial agency-specific guidance, and operates under quality system expectations that differ in material ways from finished pharmaceutical product manufacture.
This course addresses the operational reality of biologicals manufacture: the cell bank system and its lifecycle controls, the management of biological starting materials and their inherent variability, contamination control in environments where the active substance is itself biological, the comparability framework that allows manufacturing changes without re-establishing efficacy from clinical trials, viral safety considerations, the particular challenges of process validation and analytical method validation for products that cannot be fully characterised by structural analysis alone, and the inspection expectations that apply to biological manufacturing facilities.
The course is designed for professionals working in or supporting biological manufacturing operations, including those transitioning from small molecule backgrounds into biological roles, those working in CDMOs offering biological manufacturing services, and those in finished product or commercial organisations whose products contain biological active substances.
Learning Outcomes
By the end of this course, learners will be able to:
- Explain the regulatory basis for biological product GMP under EU GMP Annex 2, ICH Q5A through Q5E, and supporting regulatory frameworks, and describe how biological GMP differs from small molecule finished product and API GMP in scope, expectation and operational application.
- Distinguish between the categories of biological medicinal product covered under Annex 2, including recombinant proteins, monoclonal antibodies, vaccines, blood and plasma-derived products, allergen products and biologicals manufactured using transgenic technology.
- Describe the cell bank system, including master cell bank establishment, working cell bank derivation, cell bank characterisation, storage controls and the regulatory expectations for cell bank documentation and management.
- Explain the principles of biological starting material control, including donor selection where applicable, source material qualification, transmission of adventitious agents risk and the controls required at the starting material stage.
- Apply contamination control principles to biological manufacturing environments where conventional terminal sterilisation is not feasible and where bioburden control, viral contamination control and segregation between biological and chemical operations carry particular importance.
- Explain the comparability framework under ICH Q5E, including when comparability assessment is required, what evidence is needed to demonstrate comparability following a manufacturing change, and how comparability outcomes affect regulatory commitments and registered product specifications.
- Recognise the principles of viral safety under ICH Q5A, including viral testing, viral clearance studies, virus reduction strategies for blood and plasma products, and the regulatory expectations for adventitious agent control.
- Explain the particular challenges of process validation for biological processes, including the limits of structural characterisation, the role of analytical methods that may not fully characterise the active substance, and how the control strategy is constructed to address this complexity.
- Apply Annex 2 expectations to facility design, equipment, personnel qualification, environmental control, water systems and contamination control in biological manufacturing.
- Recognise the specific QP considerations for biological product batch certification, including the additional documentation, comparability evidence and viral safety evidence that biological batch certification requires.
- Identify how different departments contribute to biological manufacturing compliance, including production, QC, QA, microbiology, validation, engineering, regulatory affairs, procurement, technology transfer and senior leadership.
Course Content
Biological medicinal products are an increasingly large and increasingly important segment of the pharmaceutical industry. Monoclonal antibodies, recombinant therapeutic proteins, vaccines and the rapidly expanding class of biological products approved for serious diseases now account for a substantial proportion of global pharmaceutical sales and a larger proportion still of the development pipeline. The growth of biosimilars has further extended the field, and the rise of advanced therapy medicinal products has built on the biological manufacturing foundation while adding further complexity.
The regulatory framework for biological products is correspondingly mature but also distinct. EU GMP Annex 2 sets the GMP expectations for biological active substances and medicinal products for human use, supplemented by ICH Q5 series guidelines covering viral safety, cell bank establishment, biotechnological product manufacturing changes and comparability. These frameworks exist because the characteristics of biological products require expectations that small molecule GMP does not address. Recombinant protein expression depends on the integrity of the cell bank system. Vaccine manufacture depends on the controlled use of biological starting materials. Monoclonal antibody production depends on consistent fermentation, harvest and purification across batches. None of these activities is governed adequately by EU GMP Part I or Part II alone.
The comparability framework under ICH Q5E is particularly important and particularly misunderstood. Biological manufacturing processes accumulate change over the product lifecycle: scale changes, raw material supplier changes, equipment changes, facility changes and process optimisation changes are commercial necessities for products manufactured over many years. The comparability framework allows these changes to be implemented without requiring new clinical trials, provided that comparability is demonstrated through analytical, biological, non-clinical and where necessary clinical evidence. Comparability is the bridge between manufacturing change and clinical evidence; when the bridge is poorly constructed, regulatory action follows.
Viral safety considerations introduce another distinctive dimension. Mammalian cell culture manufacturing carries inherent adventitious agent risk. Blood and plasma products require demonstrated viral clearance. Vaccines manufactured using viral or cell-based systems require contamination control approaches that go well beyond environmental monitoring. Annex 2 and ICH Q5A address these expectations, and inspectors of biological manufacturing facilities give them appropriate weight.
This course is essential because biological manufacturing competence is in shorter supply than biological manufacturing demand. Professionals transitioning into biological roles from small molecule backgrounds frequently underestimate the conceptual and operational differences. Established biological manufacturing organisations face the challenge of keeping pace with regulatory expectations that continue to evolve. Finished product organisations sourcing biological active substance from third-party manufacturers carry supplier oversight obligations that require genuine understanding of the framework. The course is designed for all of these populations.
The regulatory framework for biological manufacture
The course opens by establishing the regulatory basis for biological product GMP. This includes EU GMP Annex 2, the ICH Q5 series (Q5A on viral safety, Q5B on genetic stability for r-DNA products, Q5C on stability testing for biotechnological products, Q5D on cell substrates and Q5E on comparability), relevant FDA biological product regulations and agency-specific guidance, and the relationship between biological GMP and the wider GMP framework.
Categories of biological medicinal product
A dedicated section addresses the categories of biological product covered under Annex 2 and explains how regulatory expectations differ across categories. This includes recombinant proteins and monoclonal antibodies, vaccines (live attenuated, inactivated, recombinant and conjugate), blood and plasma-derived products, allergen products and biologicals manufactured using transgenic technology. The course addresses where Annex 2 ends and where the ATMP framework begins for advanced therapy products.
The cell bank system
The cell bank system is addressed in operational depth. Learners will understand master cell bank establishment, working cell bank derivation, characterisation requirements under ICH Q5D and the relevant pharmacopoeial methods, storage and security expectations, cell bank documentation, and the lifecycle controls that apply from establishment through commercial use.
Biological starting materials and adventitious agent control
The course addresses starting material control for biological products, including donor selection criteria for human and animal-derived materials, source material qualification, the principles of adventitious agent risk assessment and the controls applied at the starting material stage to prevent introduction of viral, mycoplasma, bacterial and other contaminating agents.
Contamination control in biological manufacturing
Contamination control in biological environments is addressed with the specific attention biological products require. This includes the principles of bioburden control where terminal sterilisation is not feasible, viral contamination control in cell culture environments, segregation expectations between biological and non-biological operations and between different biological products, environmental monitoring approaches calibrated for biological manufacturing and the management of single-use systems in biological manufacturing.
Process validation for biological processes
Process validation for biological products requires particular treatment because the active substance often cannot be fully characterised by structural analysis alone. The course addresses how the control strategy is constructed for biological processes, how Critical Quality Attributes and Critical Process Parameters are established, how process performance qualification is designed and executed for biological products, and how continued process verification operates in a biological manufacturing context.
Analytical method validation for biological products
Analytical method validation for biological products is addressed in its own right. Learners will understand the role of identity, purity, potency, characterisation and impurity methods, the limits of analytical characterisation for biological products, and the principles of bioassay validation including reference standard establishment and lifecycle management.
The comparability framework under ICH Q5E
The course addresses the comparability framework in operational depth. This includes when comparability assessment is required, what evidence is needed at the analytical, biological, non-clinical and clinical levels, how comparability protocols are designed and submitted, how comparability conclusions are documented and how comparability outcomes affect regulatory commitments and registered product specifications.
Viral safety and clearance
Viral safety under ICH Q5A is addressed including testing of starting materials, in-process testing where required, viral clearance validation studies for blood and plasma products and other applicable categories, and the regulatory expectations for adventitious agent control programmes.
Cross-functional accountability and inspection readiness
A dedicated section maps Annex 2 expectations to the functions responsible for meeting them, and the final section addresses inspection readiness for biological manufacturing facilities. This includes how inspectors approach biological facilities, what they typically focus on, what common findings look like and how to prepare a biological site for inspection scrutiny.
- Biological manufacturing professionals at all levels, including production, QA, QC, microbiology, validation, regulatory affairs and senior leadership within biological manufacturing organisations.
- CDMO professionals offering biological manufacturing services and the contract partners who manage those arrangements.
- Professionals transitioning into biological manufacturing roles from small molecule backgrounds who need to build the specific competence the biological framework requires.
- Qualified Persons and QA professionals responsible for batch certification of biological products or finished products containing biological active substances.
- Regulatory Affairs professionals managing biological product submissions, comparability protocols, manufacturing changes affecting biological products and post-approval variations under the biological regulatory framework.
- Technical operations, process development, MSAT and manufacturing science teams involved in biological process design, scale-up, technology transfer and lifecycle management.
- QC microbiology, analytical development and laboratory teams responsible for biological product testing, bioassay execution, characterisation analytics and impurity analysis.
- Engineering, facilities and validation teams responsible for biological manufacturing facility design, cleanroom operation, single-use system management and process equipment qualification.
- Procurement and supplier quality teams managing biological starting materials, cell banks, single-use systems and outsourced biological manufacturing services.
- Internal auditors and inspection readiness leads working with biological manufacturing
- Senior leaders and executive teams accountable for biological manufacturing capability, capacity decisions, regulatory standing and supply continuity for biological products.
You will gain a rigorous understanding of the regulatory framework that governs biological product manufacture and the operational realities of running a GMP-compliant biological operation. You will be able to interpret EU GMP Annex 2 and the ICH Q5 series with the precision biological manufacturing requires, recognise where biological GMP diverges from small molecule frameworks and apply the right expectations in the right context.
For those in biological manufacturing roles, this course builds the regulatory authority needed to defend operational decisions, design comparability protocols, manage viral safety considerations and respond to inspection scrutiny. For those moving into biological roles from other backgrounds, it provides the conceptual bridge needed to operate effectively in a framework that differs materially from small molecule GMP.
Organisations benefit from a workforce that understands biological manufacturing as the distinct discipline it is. This strengthens process design decisions, improves comparability protocol quality, supports more credible regulatory submissions and reduces the risk of inspection findings arising from inadequate framework understanding.
For organisations expanding into biological manufacturing or onboarding biological manufacturing services, the course supports faster capability development and stronger regulatory readiness. For established biological manufacturers, it provides a structured refresh of the framework expectations that have evolved across the cell bank, comparability, viral safety and analytical method areas in particular.
- Comprehensive expert video content covering EU GMP Annex 2, the ICH Q5 series, biological manufacturing operations, comparability, viral safety and biological-specific quality system
- Real-world case studies from biological manufacturing, vaccine production, monoclonal antibody manufacture, biosimilar development and biological CDMO environments.
- Practical examples of cell bank lifecycle management, comparability protocol design, viral clearance validation and biological process validation.
- Cross-functional scenarios showing how production, QC, QA, regulatory affairs, technology transfer and senior leadership affect biological manufacturing compliance.
- Exercises on comparability assessment, manufacturing change impact, biological audit conduct and biological inspection preparation.
- Inspection-readiness scenarios focused on defending biological manufacturing decisions across the framework.
- Multi-choice assessment examination.
- Certificate of completion upon passing the assessment.
Course Details
Instructor(s):
Paul Palmer & Farah Nadeem
Level:
Mastery
Duration:
3.5 Hours
Type:
Instructor led
Launch Yourself Into The Future.
Join Academy Pharmaceutical Excellence to gain industry-leading knowledge and skills through our comprehensive courses designed for aspiring professionals.